New York Life Investment Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

New York Life Investment Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-255,584	Closed	-$15M	–	1580
2023 Q4	$15M	Buy	+255,584	New	+$14.4M	0.15%	128

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

New York Life Investment Management's MRTX Position: Q1 2024 in Review

New York Life Investment Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 255,584 shares — an estimated $15M sold.

New York Life Investment Management first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $15M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

New York Life Investment Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
New York Life Investment Management sold 255,584 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $15M.
New York Life Investment Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
New York Life Investment Management's Mirati Therapeutics, Inc. Common Stock position peaked at $15M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.